Superior chronic tolerability of adjunctive modafinil compared to pramipexole in treatment-resistant bipolar disorder

Journal of Affective Disorders

Volumn 150, Issue 1, 2013, Pages 130-135

  Dell'Osso, Bernardo ^a   Timtim, Sara ^b   Hooshmand, Farnaz ^b   Miller, Shefali ^b,c   Wang, Po W ^b   Hill, Shelley J ^b   Portillo, Natalie ^b   Ketter, Terence A ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Bipolar disorder; Long term; Modafinil; Pramipexole; Tolerability

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATOMOXETINE; CARBAMAZEPINE; CLOZAPINE; LAMOTRIGINE; LITHIUM; MODAFINIL; NEUROLEPTIC AGENT; PRAMIPEXOLE; VALPROIC ACID; ZONISAMIDE;

ADULT; ARTICLE; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CLINICAL STUDY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPOMANIA; MAJOR CLINICAL STUDY; MALE; MANIA; NAUSEA; OUTPATIENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; SEDATION; SIDE EFFECT; TREATMENT DURATION; VOMITING;

BIPOLAR DISORDER; LONG-TERM; MODAFINIL; PRAMIPEXOLE; TOLERABILITY;

ADULT; BENZHYDRYL COMPOUNDS; BENZOTHIAZOLES; BIPOLAR DISORDER; CHEMOTHERAPY, ADJUVANT; DRUG TOLERANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PSYCHOTROPIC DRUGS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84880924462     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2012.11.030     Document Type: Article

References (38)

1. C.B. Aiken Pramipexole in psychiatry: a systematic review of the literature Journal of Clinical Psychiatry 68 8 2007 1230 1236
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders fourth ed. 2000 American Psychiatric Assoc. Washington, DC. text revision
3. A. Antonini, and D. Calandrella Pharmacokinetic evaluation of pramipexole Expert Opinionon on Drug Metabolsim & Toxicology 7 10 2011 1307 1314
4. J.P. Bennett Jr, and M.F. Piercey Pramipexole - a new dopamine agonist for the treatment of Parkinson's disease Journal of the Neurological Sciences 163 1 1999 25 31
5. J.R. Calabrese, T.A. Ketter, J.M. Youakim, J. Tiller, R. Yang, and M.A. Frye Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study Journal of Clinical Psychiatry 71 10 2010 1363 1370
6. P. Cassano, L. Lattanzi, F. Soldani, S. Navari, G. Battistini, A. Gemignani, and G.B. Cassano Pramipexole in treatment-resistant depression: an extended follow-up Depress Anxiety 20 3 2004 131 138
7. Dell'osso B.; Ketter T.A.; 2012a. Use of adjunctive stimulants in adult bipolar depression. International Journal of Neuropsychopharmacology. In press.
8. Dell'Osso B.; Ketter T.A. 2012b Use of Adjunctive Pramipexole in Bipolar Depression. Submitted
9. R.S. El-Mallakh, P. Penagaluri, A. Kantamneni, Y. Gao, and R.J. Roberts Long-term use of pramipexole in bipolar depression: a naturalistic retrospective chart review Psychiatry Quarterly 81 3 2010 207 213
10. J. Endicott, R.L. Spitzer, J.L. Fleiss, and J. Cohen The global assessment scale: a procedure for measuring overall severity of psychiatric disturbance Archive General Psychiatry 33 6 1976 766 771
11. M.A. Frye, H. Grunze, T. Suppes, S.L. McElroy, P.E. Keck Jr, J. Walden, G.S. Leverich, L.L. Altshuler, S. Nakelsky, S. Hwang, J. Mintz, and R.M. Post A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression American Journal of Psychiatry 164 8 2007 1242 1249
12. M. Gerlach, K. Double, T. Arzberger, F. Leblhuber, T. Tatschner, and P. Riederer Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum Journal of Neural Transmission 110 10 2003 1119 1127
13. S.N. Ghaemi, D.J. Hsu, F. Soldani, and F.K. Goodwin Antidepressants in bipolar disorder: the case for caution Bipolar Disorder 5 6 2003 421 433
14. rd, K. Kurita, J.C. Hoblyn, S.N. Ghaemi, R.H. Perlis, D.J. Miklowitz, T.A. Ketter, G.S. Sachs, and M.E. Thase Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder Journal of Clinical Psychiatry 70 2 2009 155 162
15. J.F. Goldberg, K.E. Burdick, and C.J. Endick Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression American Journal of Psychiatry 161 3 2004 564 566
16. H. Grunze, E. Vieta, G.M. Goodwin, C. Bowden, R.W. Licht, H.J. Möller, and S. Kasper WFSBP - task force on treatment guidelines for bipolar disorders, 2010. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2010 on the treatment of acute bipolar depression World Journal of Biological Psychiatry 11 2 2010 81-109
17. H.C. Grunze Switching, induction of rapid cycling, and increased suicidality with antidepressants in bipolar patients: fact or overinterpretation? CNS Spectrums 13 9 2008 790 795
18. E.V. Gurevich, and J.N. Joyce Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons Neuropsychopharmacology 20 1 1999 60 80
19. T. Hensch, H. Himmerich, and U. Hegerl Stimulants in bipolar disorder: beyond common beliefs CNS Spectrums 15 7 2010 469 470
20. L.L. Judd, P.J. Schettler, D.A. Solomon, J.D. Maser, W. Coryell, J. Endicott, and H.S. Akiskal Psychosocial disability and work role function compared across the long-term course of bipolar I, bipolar II and unipolar major depressive disorders Journal of Affective Disorders 108 1-2 2008 49 58
21. D. Lévesque, J. Diaz, C. Pilon, M.P. Martres, B. Giros, E. Souil, D. Schott, J.L. Morgat, J.C. Schwartz, and P. Sokoloff Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin Proceedings of the National Academy of Sciences - USA 89 17 1992 8155 8159
22. K.R. Merikangas, H.S. Akiskal, J. Angst, P.E. Greenberg, R.M. Hirschfeld, M. Petukhova, and R.C. Kessler Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication Archive General Psychiatry 64 5 2007 543 552
23. J. Mierau, F.J. Schneider, H.A. Ensinger, C.L. Chio, M.E. Lajiness, and R.M. Huff Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors European Journal of Pharmacology 290 1 1995 29 36
24. M.J. Minzenberg, and C.S. Carter Modafinil: a review of neurochemical actions and effects on cognition Neuropsychopharmacology 33 7 2008 1477 1502
25. S. Nasr, B. Wendt, and K. Steiner Absence of mood switch with and tolerance to modafinil: a replication study from a large private practice Journal of Affective Disorders 95 1-3 1995 111 114
26. M.F. Piercey, E.L. Walker, D.L. Feldpausch, and M. Camacho-Ochoa High affinity binding for pramipexole, a dopamine D3 receptor ligand, in rat striatum Neuroscience Letters 219 2 1996 138 140
27. D.T. Plante Treatment-emergent hypomania or mania with modafinil American Journal of Psychiatry 165 1 2008 134 135
28. G.S. Sachs, C. Guille, and S.L. McMurrich A clinical monitoring form for mood disorders Bipolar Disorders 4 5 2002 323 327
29. G.S. Sachs, M.E. Thase, M.W. Otto, M. Bauer, D. Miklowitz, S.R. Wisniewski, P. Lavori, B. Lebowitz, M. Rudorfer, E. Frank, A.A. Nierenberg, M. Fava, C. Bowden, T.A. Ketter, L. Marangell, J. Calabrese, S. Kupfer, and J.F. Rosenbaum Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD) Biological Psychiatry 53 11 2003 1028 1042
30. K.C. Schmitt, and M.E.A. Reith The atypical stimulant and nootropic modafinil interacts with the dopamine transporter in a different manner than classical cocaine-like inhibitors PLoS ONE 6 10 2011 e25790
31. V. Sharma, and A. Smith A case of mania following the use of pramipexole American Journal of Psychiatry 164 2 2007 351
32. D.V. Sheehan, Y. Lecrubier, and K.H. Sheehan The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10 Journal of Clinical Psychiatry 59 suppl 20 1998 22 33
33. M.K. Spearing, P.M. Post, G.S. Leverich, D. Brandt, and W. Nolen Modification of the clinical global impression (CGI) scale for use in bipolar illness (BP): the CGI-BP Psychiatry Research 73 3 1997 159 171
34. S.K. Vosburg, C.L. Hart, M. Haney, E. Rubin, and R.W. Foltin Modafinil does not serve as a reinforcer in cocaine abusers Drug and Alcohol Dependence 106 2,3 2010 233 236
35. P. Willner, S. Lappas, S. Cheeta, and R. Muscat Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole Psychopharmacology (Berl) 115 4 1994 454 462
36. L.N. Yatham, S.H. Kennedy, A. Schaffer, S.V. Parikh, S. Beaulieu, C. O'Donovan, G. MacQueen, R.S. McIntyre, V. Sharma, A. Ravindran, L.T. Young, A.H. Young, M. Alda, R. Milev, E. Vieta, J.R. Calabrese, M. Berk, K. Ha, and F. Kapczinski Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009 Bipolar Disorder 11 3 2009 225 255
37. C.A. Zarate Jr, J.L. Payne, J. Singh, J.A. Quiroz, D.A. Luckenbaugh, K.D. Denicoff, D.S. Charney, and H.K. Manji Pramipexole for bipolar II depression: a placebo-controlled proof of concept study Biological Psychiatry 56 1 2004 54 60
38. D. Zolkowska, R. Jain, R.B. Rothman, J.S. Partilla, B.L. Roth, V. Setola, T.E. Prisinzano, and M.H. Baumann Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil Journal of Pharmacology and Experimental Therapeutics 329 2 2009 738 746